Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 94.71 | — | — | — | 40.39 | — | 89.12 | — | 6.21 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | +551.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.62 | 1.75 | 3.87 | 4.23 | 1.11 | 1.34 | 1.20 | 0.81 | 0.85 | 0.75 | 0.76 | 0.61 | 0.46 | 0.33 | 0.51 | 0.43 | 0.19 | 0.31 | 0.39 | 0.49 | 0.55 |
| — | +31.1% | +222.6% | +425.0% | +30.7% | +79.1% | +58.3% | +33.0% | +82.5% | +125.9% | +47.6% | +41.8% | +145.1% | +7.9% | +31.6% | -13.6% | -65.3% | -58.6% | -57.3% | -33.1% | -57.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.1% | — | — | — | 100.0% | — | 100.0% | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | 0.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -10711.2% | — | — | — | -3079.0% | — | -6954.3% | — | -494.9% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -522.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -9756.5% | — | — | — | -2954.0% | — | -6655.7% | — | -461.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -540.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.5% | -86.8% | -31.4% | -35.5% | -18.6% | -22.4% | -20.3% | -17.4% | -14.7% | -13.8% | -12.5% | -11.9% | -10.7% | -9.5% | -6.8% | -9.7% | -8.7% | -48.6% | -7.8% | -4.7% | -7.1% |
| — | -287.2% | -54.5% | -104.6% | -26.8% | -62.5% | -62.6% | -45.7% | -37.7% | -44.9% | -83.7% | -22.3% | -23.0% | +80.4% | +12.6% | -107.7% | -21.6% | -612.1% | -46.9% | +58.6% | +54.2% | |
| ROA | -62.9% | -2.1% | -23.4% | -28.2% | -15.0% | -18.1% | -17.2% | -14.8% | -12.6% | -12.2% | -11.1% | -10.5% | -9.5% | -8.7% | -6.3% | -8.9% | -7.9% | -45.5% | -7.5% | -4.5% | -6.8% |
| — | +88.6% | -35.7% | -91.2% | -18.7% | -48.4% | -54.9% | -40.7% | -32.4% | -39.7% | -77.5% | -18.2% | -20.4% | +80.8% | +16.2% | -98.0% | -16.1% | -593.1% | -46.8% | +58.1% | +51.1% | |
| ROIC | -229.7% | — | — | — | — | -314.1% | -81.5% | -48.1% | -27.1% | -33.4% | -26.7% | -21.3% | -19.7% | -16.3% | -15.3% | -15.2% | -13.0% | -62.7% | -8.0% | -6.9% | -6.7% |
| — | — | — | — | — | -841.2% | -204.7% | -126.4% | -37.9% | -104.6% | -74.7% | -40.0% | -51.5% | +74.0% | -90.5% | -120.4% | -94.9% | -969.4% | -30.4% | +44.3% | +72.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | — | — | — | — | — | -51.2% | -8.9% | +33.2% | +73.9% | -30.2% | -42.0% | -52.0% | -59.2% | -2.8% | -2.2% | -5.8% | +114.7% | +60.7% | +45.6% | -59.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.76 | 14.09 | 3.69 | 4.23 | 5.76 | 4.72 | 5.77 | 7.52 | 6.16 | 8.03 | 9.42 | 8.92 | 8.18 | 11.15 | 14.10 | 12.35 | 11.26 | 12.09 | 22.33 | 32.38 | 21.27 |
| — | +198.4% | -36.1% | -43.7% | -6.4% | -41.2% | -38.7% | -15.7% | -24.7% | -28.0% | -33.2% | -27.8% | -27.3% | -7.8% | -36.8% | -61.9% | -47.0% | -51.8% | -20.3% | +26.0% | +111.0% | |
| Quick Ratio | 5.76 | 14.09 | 3.69 | 4.23 | 5.76 | 4.72 | 5.77 | 7.52 | 6.16 | 8.03 | 9.42 | 8.92 | 8.18 | 11.15 | 14.10 | 12.35 | 11.26 | 12.09 | 22.33 | 32.38 | 21.27 |
| — | +198.4% | -36.1% | -43.7% | -6.4% | -41.2% | -38.7% | -15.7% | -24.7% | -28.0% | -33.2% | -27.8% | -27.3% | -7.8% | -36.8% | -61.9% | -47.0% | -51.8% | -20.3% | +26.0% | +111.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -4.76 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LSTA stock.
Lisata Therapeutics, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lisata Therapeutics, Inc.'s current operating margin is -10711.2%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lisata Therapeutics, Inc.'s business trajectory between earnings reports.